Researchers at Cedars-Sinai Cancer and Johns Hopkins University discovered a novel three-step treatment that disrupts the pancreatic tumor microenvironment in laboratory mice.
Cleveland Clinic researchers measured cellular interactions in a simplified tumor environment consisting of drug-resistant non-small cell lung cancer cells and drug-sensitive precursor cells, aiming to better understand how therapeutic resistance develops.
Results from the pivotal phase II MOUNTAINEER trial showed Tukysa (tucatinib) in combination with trastuzumab was well-tolerated with durable responses in patients with previously treated HER2-positive metastatic colorectal cancer.
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute identified key features of a gene mutation responsible for 15-20% of all melanomas.
The SWOG Cancer Research Network has partnered with cloud clinical research software company nCoup to pilot and deploy the company’s nCartes platform at SWOG sites to help advance data collection.
A report led by researchers at the American Cancer Society, in collaboration with NCI, showed that more than 18 million Americans (8.3 million males and 9.7 million females) with a history of cancer were living in the United States as of Jan. 1, 2022, with over 12 million (67%) aged 65 years or older.
Researchers at Winship Cancer Institute of Emory University found that COVID-19 vaccines are much less effective for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia, particularly those ages 65 and older. After vaccination, many of these patients produced low or no antibodies that bind or neutralize SARS-CoV-2 and its variants of concern, particularly Omicron.
University of Texas Southwestern researchers developed a blood test to predict which nonalcoholic fatty liver disease patients are most likely to develop hepatocellular carcinoma.
Researchers from Cedars-Sinai Cancer analyzed patient samples and studies conducted in animal models to identify a novel role for the IL-27 signaling pathway in hepatocellular carcinoma.
Researchers at The University of Texas MD Anderson Cancer Center developed an approach to quantify tumor-specific total mRNA levels from patient tumor samples, which contain both cancer and non-cancer cells.
